The FDA has issued final guidelines on compounding of oral oxitriptan drugs as a treatment for tetrahydrobiopterin deficiency, saying it doesn't plan to take regulatory action against pharmacists or physicians in such cases. The move follows a February final rule from the FDA, which included oxitriptan on a list of substances that cannot be used for compounding.
Final guidance on oral oxitriptan product compounding issued by FDA
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.